Domů › Rakovina endometria › Oklahoma › Oklahoma City
Klinické studie Rakovina endometria v Oklahoma City, OK
25 studií pro Rakovina endometria hledá účastníky v lokalitách v Oklahoma City a okolí (do cca 30 mil). Otevřete studii a zjistěte, kdo se může zapojit a jak kontaktovat tým studie.
Oficiální text studie (anglicky)
Hledáte účastníky pro studii? Zvýrazněte ji nahoře na této stránce – $99 na 30 dní →
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Probíhá náborFáze 3
- University of Oklahoma Health Sciences Center, Oklahoma City
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Probíhá náborFáze 2
- University of Oklahoma Health Sciences Center, Oklahoma City
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Probíhá náborFáze 1/2
- University of Oklahoma, Oklahoma City
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
Probíhá náborFáze 1
- University of Oklahoma Health Sciences Center, Oklahoma City
Study of AVZO-021 in Patients With Advanced Solid Tumors
Probíhá náborFáze 1/2
- Avenzo Therapeutics Recruiting Site, Oklahoma City
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
Probíhá náborFáze 2
- University of Oklahoma Health Sciences Center, Oklahoma City
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Probíhá náborFáze 1/2
- Stephenson Cancer Center, Oklahoma City
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
Probíhá náborFáze 2
- University of Oklahoma Health Sciences Center, Oklahoma City
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Probíhá náborFáze 1/2
- University of Oklahoma, Oklahoma City
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
Probíhá náborFáze 3
- Peggy & Charles Stephenson Oklahoma Cancer Center, Oklahoma City
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Probíhá náborFáze 3
- Research Site, Oklahoma City
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Probíhá náborFáze 1
- OU Health Stephenson Cancer Center, Oklahoma City
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
Probíhá náborFáze 2
- Stephenson Cancer Center at OU Health, Oklahoma City
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Probíhá náborFáze 1
- Normunity Investigational Site, Oklahoma City
A Study of DM002 in Patients With Advanced Solid Tumors
Probíhá náborFáze 1/2
- University of Oklahoma Health Sciences Center, Oklahoma City
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Probíhá náborFáze 1/2
- University of Oklahoma - Health Sciences Center, Oklahoma City
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Probíhá náborFáze 1/2
- Stephenson Cancer Center, Oklahoma City
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Probíhá náborFáze 1/2
- Stephenson Cancer Center Oklahoma University Health, Oklahoma City
Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
Probíhá náborObservační studie
- Mercy Hospital - OKC, Oklahoma City
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
Probíhá náborFáze 1/2
- University of Oklahoma Health Stephenson Cancer Center, Oklahoma City
Uterine Preservation Via Lifestyle Transformation
Probíhá náborFáze 2
- University of Oklahoma, Oklahoma City
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Probíhá náborFáze 1
- Dren Investigational Site, Oklahoma City
Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
Probíhá náborFáze 1
- University of Oklahoma, Oklahoma City
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
Probíhá náborFáze 2
- Oklahoma University Stephenson Cancer Center, Oklahoma City
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
Probíhá náborFáze 2
- University of Oklahoma, Oklahoma City
Studie Rakovina endometria v jiných městech
- Houston, TX68 studií
- New York City, NY52 studií
- Boston, MA50 studií
- Arlington, VA39 studií
- Nashville, TN38 studií
- Los Angeles, CA34 studií
- St. Louis, MO29 studií
- Philadelphia, PA28 studií
- San Antonio, TX27 studií
- Columbus, OH25 studií
- Chicago, IL25 studií
- Queens, NY25 studií
Další studie v Oklahoma City
- Nemalobuněčný plicní karcinom28 studií
- Rakovina vaječníků28 studií
- Kolorektální karcinom22 studií
- Rakovina prostaty21 studií
- Rakovina plic19 studií
- Rakovina prsu17 studií
- Metastatický karcinom16 studií
- Rakovina (všechny typy)14 studií
- Akutní myeloidní leukemie14 studií
- Squamózní buněčný karcinom hlavy a krku13 studií
- Rakovina močového měchýře11 studií
- Rakovina slinivky břišní11 studií
Zdroj: ClinicalTrials.gov, data načtena 6. 10. 2026. Každá studie má vlastní kritéria způsobilosti; o účasti rozhoduje tým studie.